Clinical trials: Melanoma Stage III
NSCLC, Melanoma
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
- Trial name
- NCT05180799
- Testing
- BA3071, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Australia
- Volunteers
- 320 people
- Sponsor
- BioAtla, Inc.
Melanoma Stage III
Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT)
Background: Standard treatment for stage III melanoma with lymph node metastases involves complete lymph node dissection, which is a radical surgical procedure aimed at the removal of the entire regional lymph node basin.
- Trial name
- NCT05445752
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Hospital Universitario Virgen Macarena
Metastatic Melanoma
Radiotherapy & Combi in Metastatic Melanoma
The purpose of this study is to investigate the side effects and safety, and effectiveness of combining dabrafenib and trametinib with radiotherapy.
- Trial name
- CombiRT (NCT02392871)
- Testing
- Palliative radiotherapy, Dabrafenib and trametinib (combination)
- Where
- 3 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Metastatic Melanoma (Stage IIIC Non-résécable or no Surgically Curable or Stage IV With Classification AJCC)
Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma
In western countries, melanoma represents a major mistake of public health by its frequency, lethality and the increasing of incidence. Surgery can cure melanoma diagnosed very early.
- Trial name
- NCT01840007
- Testing
- Metformin Group
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Melanoma
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
The purpose of this study is to determine the effects of combination treatment of Nivolumab with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated advanced Melanoma.
- Trial name
- CheckMate 401 (NCT02599402)
- Testing
- Nivolumab, Ipilimumab
- Where
- 111 sites in Australia, Austria and 10 more
- Volunteers
- 533 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma, Metastatic Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
It is nowadays well established that the immune system can profoundly influence disease outcome in cancer patients. Increasing evidence is indeed showing that patients displaying spontaneous T cell-mediated immune response…
- Conditions
- Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- SERPENTINE (NCT04941365)
- Testing
- single arm
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Melanoma
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
This will show if CP-675,206 can be administered safely as an intravenous infusion lasting one hour. CP 675,206 already has been administered to 835 subjects over 1.0 - 7.5 hours.
- Trial name
- NCT00585000
- Testing
- CP-675,206
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
This phase II trial tests how well lifileucel, with reduce dose fludarabine and cyclophosphamide for lymphodepletion and interleukin-2, work for treating patients with melanoma that cannot be removed by surgery (unresectable) or…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Trial name
- NCT06151847
- Testing
- Biospecimen Collection, Cyclophosphamide, Echocardiography
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Kansas Medical Center
Metastatic Melanoma
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body.
- Trial name
- NCT02009397
- Testing
- Ipilimumab, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Louisville
Melanoma
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
- Trial name
- RELATIVITY-098 (NCT05002569)
- Testing
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 1,093 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body.
- Conditions
- Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03727789
- Testing
- FACT Complex-targeting Curaxin CBL0137
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma (Skin)
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
RATIONALE: Monoclonal antibodies, such as ticilimumab (CP-675,206), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00471887
- Testing
- CP-675,206
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unresectable Melanoma, Metastatic Melanoma
Sargramostim (GM-CSF) + PD-1
This research study is testing the combination of two drugs, sargramostim and pembrolizumab. The study is designed to see if the combination of these study drugs would improve the control of unresectable or metastatic melanoma…
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT04703426
- Testing
- Sargramostim (GM-CSF), Pembrolizumab (anti-PD-1)
- Sponsor
- Dana-Farber Cancer Institute
Melanoma (Skin)
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00470015
- Testing
- MART-1 antigen, IL-2, gp100 antigen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.
- Trial name
- NCT00002817
- Testing
- sargramostim, vaccinia-GM-CSF vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Melanoma (Skin)
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070343
- Testing
- oblimersen sodium, dacarbazine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Melanoma Stage IIIc, Melanoma Stage IV
Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients
A new cancer vaccine called TRIMELVax will be tested as a potential treatment for patients with unresectable stage III or stage IV melanoma who have progressed to anti-PD1 immune checkpoint blockers treatment or who have…
- Trial name
- Trimelvax001 (NCT06556004)
- Testing
- TRIMELVAX
- Where
- 2 sites in Chile
- Volunteers
- 20 people
- Sponsor
- University of Chile
Recurrent Melanoma, Stage IIIA Melanoma
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of cabozantinib-s-malate when given together with vemurafenib in treating patients with solid tumors or melanoma that is metastatic or that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT01835184
- Testing
- cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)